2020
DOI: 10.1007/s00381-020-04712-5
|View full text |Cite
|
Sign up to set email alerts
|

Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment

Abstract: Introduction Hemangioblastomas are rare, histologically benign, highly vascularized tumors of the brain, the spinal cord, and the retina, occurring sporadically or associated with the autosomal dominant inherited von Hippel-Lindau (VHL) disease. Children or adults with VHL disease have one of > 300 known germline mutations of the VHL gene located on chromosome 3. They are prone to develop hemangioblastomas, extremely rarely starting at age 6, rarely at age 12–18, and, typically and almost all,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
38
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 33 publications
(46 citation statements)
references
References 54 publications
(84 reference statements)
1
38
0
1
Order By: Relevance
“…Although the optimal surgical timing for resection of VHL-associated CNS HGBs and the effect of radiotherapy and chemotherapy remain unclear, tumor resection is currently the mainstay of therapy for VHL-associated CNS HGBs. The standard surgical approach for CNS HGBs is craniotomy and microsurgical treatment, which has the advantages of versatility and applicability for repeated surgeries using the same strategy and the disadvantage of invasiveness ( 6 , 10 , 32 ). Endoscopic transcranial surgery, a novel and emerging operation, is minimally invasive, but it is not clear whether it can achieve the same level of efficacy as conventional craniotomy ( 33 ).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Although the optimal surgical timing for resection of VHL-associated CNS HGBs and the effect of radiotherapy and chemotherapy remain unclear, tumor resection is currently the mainstay of therapy for VHL-associated CNS HGBs. The standard surgical approach for CNS HGBs is craniotomy and microsurgical treatment, which has the advantages of versatility and applicability for repeated surgeries using the same strategy and the disadvantage of invasiveness ( 6 , 10 , 32 ). Endoscopic transcranial surgery, a novel and emerging operation, is minimally invasive, but it is not clear whether it can achieve the same level of efficacy as conventional craniotomy ( 33 ).…”
Section: Discussionmentioning
confidence: 99%
“…Recently, stereotactic radiosurgery (SRS) has been investigated as an alternative treatment modality for CNS HGBs, and it is more suitable for patients with multiple or recurrent tumors and nonsurgical candidates ( 37 , 38 ). When it comes to pediatric patients, the potential risk of late sequelae should not be ignored ( 32 , 39 ). In addition, novel drugs have been developed based on the key pathways involved in HGB development, and their safety and effectiveness are being evaluated by several clinical studies ( 1 , 6 , 40 , 41 ).…”
Section: Discussionmentioning
confidence: 99%
“…It can be affected by the depth of anesthesia and a closed-loop communication between anesthesiologist and neurophysiology is crucial to avoid this undesirable intraoperative event. The correct identification of neural structures, such as cranial nerves and ascending and descending tracts, related to sensibility and motor function is directly related to decreased morbidity [ 29 ].…”
Section: Discussionmentioning
confidence: 99%
“…2018; Klingler et al. 2020). Peripheral RHs are identified in approximately 85% and juxtapapillary lesions in 15% of patients (Wong et al.…”
Section: Introductionmentioning
confidence: 99%